ArticleTheranostics2026

Targeting USP22 reprograms the tumor microenvironment and sensitizes KRAS/p53-driven lung cancer to anti-PD-1 immunotherapy.

Keqiang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.